Oppenheimer Maintains Outperform on Boston Scientific, Lowers Price Target to $85

Benzinga · 1d ago
Oppenheimer analyst Suraj Kalia maintains Boston Scientific (NYSE:BSX) with a Outperform and lowers the price target from $90 to $85.